EKF Diagnostics (EKF) Competitors GBX 26.20 -1.20 (-4.38%) (As of 11:49 AM ET) Add Compare Share Share Competitors Stock AnalysisChartCompetitorsDividendHeadlinesInsider Trades EKF vs. MXCT, NIOX, CREO, IUG, NCYT, POLX, BELL, IHC, AVO, and RUAShould you be buying EKF Diagnostics stock or one of its competitors? The main competitors of EKF Diagnostics include MaxCyte (MXCT), NIOX Group (NIOX), Creo Medical Group (CREO), Intelligent Ultrasound Group (IUG), Novacyt (NCYT), Polarean Imaging (POLX), Belluscura (BELL), Inspiration Healthcare Group (IHC), Advanced Oncotherapy (AVO), and RUA Life Sciences (RUA). These companies are all part of the "medical devices" industry. EKF Diagnostics vs. MaxCyte NIOX Group Creo Medical Group Intelligent Ultrasound Group Novacyt Polarean Imaging Belluscura Inspiration Healthcare Group Advanced Oncotherapy RUA Life Sciences MaxCyte (LON:MXCT) and EKF Diagnostics (LON:EKF) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their media sentiment, institutional ownership, analyst recommendations, earnings, valuation, risk, community ranking, profitability and dividends. Is MXCT or EKF more profitable? EKF Diagnostics has a net margin of 9.37% compared to MaxCyte's net margin of -77.97%. EKF Diagnostics' return on equity of 7.58% beat MaxCyte's return on equity.Company Net Margins Return on Equity Return on Assets MaxCyte-77.97% -15.33% -11.07% EKF Diagnostics 9.37%7.58%5.27% Does the MarketBeat Community prefer MXCT or EKF? EKF Diagnostics received 174 more outperform votes than MaxCyte when rated by MarketBeat users. Likewise, 76.76% of users gave EKF Diagnostics an outperform vote while only 68.92% of users gave MaxCyte an outperform vote. CompanyUnderperformOutperformMaxCyteOutperform Votes15368.92% Underperform Votes6931.08% EKF DiagnosticsOutperform Votes32776.76% Underperform Votes9923.24% Do institutionals and insiders believe in MXCT or EKF? 70.5% of MaxCyte shares are held by institutional investors. Comparatively, 70.3% of EKF Diagnostics shares are held by institutional investors. 1.5% of MaxCyte shares are held by insiders. Comparatively, 5.2% of EKF Diagnostics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term. Which has more volatility and risk, MXCT or EKF? MaxCyte has a beta of 1.13, indicating that its stock price is 13% more volatile than the S&P 500. Comparatively, EKF Diagnostics has a beta of 0.57, indicating that its stock price is 43% less volatile than the S&P 500. Does the media favor MXCT or EKF? In the previous week, MaxCyte's average media sentiment score of 0.00 equaled EKF Diagnostics'average media sentiment score. Company Overall Sentiment MaxCyte Neutral EKF Diagnostics Neutral Which has preferable earnings & valuation, MXCT or EKF? EKF Diagnostics has higher revenue and earnings than MaxCyte. MaxCyte is trading at a lower price-to-earnings ratio than EKF Diagnostics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioMaxCyte£45.44M7.26-£35.43M-£0.26-1,207.69EKF Diagnostics£50.95M2.33£4.78M£0.012,620.00 SummaryEKF Diagnostics beats MaxCyte on 10 of the 13 factors compared between the two stocks. Ad DarwinMarket Winners Post-Election: Your Exclusive Report InsideThe dust has settled on the 2024 elections, and markets are already responding to the new political landscape. Now is the perfect time to adjust your strategy and take advantage of fresh opportunities emerging from these developments. We’re excited to share our updated report, “Post-Election Investment Gems: Top Stocks Set to Thrive in 2025.” This guide is designed to equip you with timely insights and actionable strategies in today’s evolving market.[Download your free report now] to stay ahead of the curve and uncover market opportunities you can’ Get EKF Diagnostics News Delivered to You Automatically Sign up to receive the latest news and ratings for EKF and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart EKF vs. The Competition Export to ExcelMetricEKF DiagnosticsMedical Devices IndustryMedical SectorLON ExchangeMarket Cap£118.88M£2.25B£5.17B£1.94BDividend Yield4.65%2.37%4.96%5.20%P/E Ratio2,620.00213.5587.141,914.45Price / Sales2.33202.341,125.75480,342.91Price / Cash10.6415.3843.2729.14Price / Book1.754.244.823.01Net Income£4.78M£77.46M£120.07M£183.02M7 Day Performance-2.60%6.18%1.02%21.48%1 Month Performance2.95%11.46%16.06%26.71%1 Year Performance-17.22%11.97%28.43%153.07% EKF Diagnostics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)EKFEKF DiagnosticsN/AGBX 26.20-4.4%N/A-13.7%£118.88M£50.95M2,620.00356Gap DownMXCTMaxCyteN/AGBX 334+2.1%N/A-2.9%£351.00M£45.44M-1,284.6280NIOXNIOX GroupN/AGBX 63.20flatN/A-4.5%£268.05M£39M3,160.0092CREOCreo Medical GroupN/AGBX 19.44+1.0%N/A-59.4%£70.31M£30.30M-323.92279IUGIntelligent Ultrasound GroupN/AGBX 12.70flatN/A+35.8%£41.53M£9.88M-1,270.0065NCYTNovacytN/AGBX 49.99+1.0%N/A-18.5%£35.31M£18.56M-96.13120POLXPolarean ImagingN/AGBX 1.35+5.9%N/A-77.8%£16.34M£1.87M-67.5028Gap UpBELLBelluscuraN/AGBX 9.50+2.7%N/A-58.9%£16.00M£1.80M-95.0024Gap UpIHCInspiration Healthcare GroupN/AGBX 12.60+0.8%N/A-68.3%£11.30M£34.30M-90.00224News CoverageAVOAdvanced OncotherapyN/AN/AN/AN/A£9.50MN/A-25.003,900Gap DownRUARUA Life SciencesN/AGBX 10.52-4.4%N/A+11.7%£6.53M£2.19M-263.0048 Related Companies and Tools Related Companies MXCT Competitors NIOX Competitors CREO Competitors IUG Competitors NCYT Competitors POLX Competitors BELL Competitors IHC Competitors AVO Competitors RUA Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (LON:EKF) was last updated on 12/30/2024 by MarketBeat.com Staff From Our Partners Is Starlink Set For The Largest IPO In History?He turned PayPal from a tiny, off-the-radar startup… to a massive $64 billion giant. Then, he did it again ...Paradigm Press | Sponsoredliberals FOOLED by Elon’s shocking surpriseElon Musk and Donald Trump fooled everyone. They said it was to “save free speech”... Or “fix what the l...StocksToTrade | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | SponsoredBuy this Stock before Trump Takes Office!To make sure everyone has the opportunity to get in, closes for good at midnight on January 1st, we're lowerin...Behind the Markets | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowIt’s here. This is the moment we’ve been waiting for. The next 3-6 months in crypto will be absolutely life...Crypto Swap Profits | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Starting with what I call Exec. Order 001. It’s a bombshell law that I believe Trump will sign within minut...Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | Sponsored3 CENT Crypto to Explode December 16th?Chris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding EKF Diagnostics Holdings plc Please log in to your account or sign up in order to add this asset to your watchlist. Share EKF Diagnostics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
